Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7034593 | 0.91 | CYP2C19 (0.40) | MEN1KMT2ACYP1A2CYP2A6CYP2C19 | |
| SCHEMBL3277029 | 0.81 | CYP1A2 (0.57) | MEN1KMT2ACYP1A2CYP2A6CYP2C19 | |
| SCHEMBL121688 | 0.80 | CYP1A2 (0.58) | MEN1KMT2ACYP1A2CYP2A6CYP2C19 | |
| SCHEMBL1050239 | 0.80 | TAAR1 (0.56) | MEN1KMT2ACYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL29453640 | 0.80 | CYP1A2 (0.58) | MEN1KMT2ACYP1A2CYP2A6CYP2C19 | |
| Toluene SCHEMBL18150068 | 0.79 | TAAR1 (0.47) | MEN1KMT2ACYP2C19CYP2D6CYP3A4 | |
| Acetaldehyde SCHEMBL8474948 | 0.74 | CYP1A2 (0.48) | MEN1KMT2ACYP1A2CYP2C19CYP2D6 | |
| SCHEMBL23527419 | 0.73 | CYP2C19 (0.55) | MEN1KMT2ACYP1A2CYP2A6CYP2C19 | |
| 1,4-Dimethoxybenzene SCHEMBL11332999 | 0.71 | L3MBTL1 (0.59) | MEN1KMT2ACYP1A2CYP2C19CYP2D6 | |
| SCHEMBL2295689 | 0.70 | CYP2C19 (0.46) | MEN1KMT2ACYP1A2CYP2A6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030083315-A1 | Human chymase inhibitors | TEIJIN LIMITED (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1167360-A9 | HUMAN CHYMASE INHIBITORS | TEIJIN LIMITED (JP) | 2002-05-15 | — | — | EP | disclosed |
| EP-1167360-A1 | HUMAN CHYMASE INHIBITORS | TEIJIN LIMITED (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083315-A1 | Human chymase inhibitors | CMA1, CTRL, CPA4 | MEN1 3405/4885KMT2A 2450/4885CYP1A2 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.